PetCaseFinder

Peer-reviewed veterinary case report

Neutrophil-to-lymphocyte ratio changes in puppies with parvovirus

By Muñoz, Adriana I et al.·Published in Frontiers in veterinary science·2022·Unidad de Desarrollo e Investigaci&#xf3·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and without an immunomodulator in puppies.

Species:
dog

Plain-English summary

A group of 26 puppies with severe diarrhea and vomiting due to parvovirus infection were treated for sepsis, a serious condition that can occur with this illness. Some puppies received a special medication called an immunomodulator to help their immune system. After 24 hours, both treatment groups showed improvement, but the puppies that received the immunomodulator had better immune responses and overall health. This suggests that using the immunomodulator can help puppies recover more effectively from parvoviral infections and improve their chances of survival.

People also search for: puppy parvovirus treatment · sepsis in puppies · immunomodulator for dogs · puppy diarrhea and vomiting · parvovirus recovery in dogs

Abstract

Neutrophil-to-lymphocyte ratio (NLR) is a cheap and easy-to-obtain biomarker that mirrors the balance between innate and adaptive immunity. Cortisol and catecholamines have been identified as major drivers of NLR. High cortisol levels increase neutrophils while simultaneously decreasing lymphocyte counts. Likewise, endogenous catecholamines may cause leukocytosis and lymphopenia. Thus, NLR allows us to monitor patient severity in conditions such as sepsis. Twenty-six puppies with sepsis secondary to canine parvoviral enteritis were treated with and without an immunomodulator. Our group determined the NLR and the plasmatic cortisol levels by chemiluminescence, and norepinephrine (NE) and epinephrine (E) by HPLC during the first 72 h of clinical follow-up. Our results showed that at admission puppies presented an NLR value of 1.8, cortisol of 314.9 nmol/L, NE 3.7, and E 3.3 pmol/mL. Both treatments decreased admission NLR values after 24 h of treatment. However, only the puppies treated with the immunomodulator (I) remained without significant changes in NLR (0.7-1.4) compared to the CT group, and that showed a significant difference (< 0.01) in their NLR value (0.4-4.6). In addition, we found significant differences in the slope values between the admission and final values of NLR (< 0.005), cortisol (< 0.02), and E (< 0.05) between treatments. Then, our data suggest that the immunomodulator positively affects the number of lymphocytes and neutrophils involved in NLR as well as major drivers like cortisol and epinephrine, which is reflected in clinical parameters and survival.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36425123/